CO2022014093A2 - Compuestos para su uso en afecciones inflamatorias - Google Patents

Compuestos para su uso en afecciones inflamatorias

Info

Publication number
CO2022014093A2
CO2022014093A2 CONC2022/0014093A CO2022014093A CO2022014093A2 CO 2022014093 A2 CO2022014093 A2 CO 2022014093A2 CO 2022014093 A CO2022014093 A CO 2022014093A CO 2022014093 A2 CO2022014093 A2 CO 2022014093A2
Authority
CO
Colombia
Prior art keywords
compounds
inflammatory conditions
inflammation
relates
toll
Prior art date
Application number
CONC2022/0014093A
Other languages
English (en)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Sousa-Faro José María Fernández
Muñoz Salvador Fudio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of CO2022014093A2 publication Critical patent/CO2022014093A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de la inflamación, preferentemente la inflamación asociada con la activación de receptores de tipo Toll. La invención también se refiere al uso de compuestos para tratar la inflamación inducida por patógenos.
CONC2022/0014093A 2020-03-02 2022-09-30 Compuestos para su uso en afecciones inflamatorias CO2022014093A2 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25
PCT/EP2021/055187 WO2021175857A1 (en) 2020-03-02 2021-03-02 Compounds for use in inflammatory conditions

Publications (1)

Publication Number Publication Date
CO2022014093A2 true CO2022014093A2 (es) 2022-11-18

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2022/0014031A CO2022014031A2 (es) 2020-03-02 2022-09-30 Compuestos para su uso en infecciones víricas
CONC2022/0014093A CO2022014093A2 (es) 2020-03-02 2022-09-30 Compuestos para su uso en afecciones inflamatorias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CONC2022/0014031A CO2022014031A2 (es) 2020-03-02 2022-09-30 Compuestos para su uso en infecciones víricas

Country Status (16)

Country Link
US (2) US20230295236A1 (es)
EP (2) EP4114435A1 (es)
JP (2) JP2023517535A (es)
KR (2) KR20220151643A (es)
CN (2) CN115461067A (es)
AU (2) AU2021232535A1 (es)
BR (2) BR112022016604A2 (es)
CA (2) CA3169540A1 (es)
CL (2) CL2022002396A1 (es)
CO (2) CO2022014031A2 (es)
IL (2) IL296068A (es)
MX (2) MX2022010926A (es)
PE (2) PE20230606A1 (es)
TW (2) TW202146038A (es)
UY (2) UY39109A (es)
WO (2) WO2021175857A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
MXPA02009943A (es) 2000-04-07 2003-04-25 Univ Pennsylvania Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
JP2023517535A (ja) 2023-04-26
CN115666616A (zh) 2023-01-31
BR112022016675A2 (pt) 2022-10-11
US20230159594A1 (en) 2023-05-25
KR20220151643A (ko) 2022-11-15
CO2022014031A2 (es) 2022-10-21
KR20220150350A (ko) 2022-11-10
MX2022010921A (es) 2022-09-29
CL2022002396A1 (es) 2023-06-30
WO2021175831A3 (en) 2021-10-14
PE20230606A1 (es) 2023-04-10
AU2021231197A1 (en) 2022-10-06
EP4114433A2 (en) 2023-01-11
EP4114435A1 (en) 2023-01-11
TW202146038A (zh) 2021-12-16
IL296069A (en) 2022-11-01
CA3169544A1 (en) 2021-09-10
UY39110A (es) 2021-09-30
UY39109A (es) 2021-09-30
WO2021175831A2 (en) 2021-09-10
MX2022010926A (es) 2022-09-29
WO2021175857A1 (en) 2021-09-10
US20230295236A1 (en) 2023-09-21
CN115461067A (zh) 2022-12-09
PE20230412A1 (es) 2023-03-07
AU2021232535A1 (en) 2022-10-06
CA3169540A1 (en) 2021-09-10
CL2022002395A1 (es) 2023-06-30
BR112022016604A2 (pt) 2022-10-11
TW202144381A (zh) 2021-12-01
JP2023517536A (ja) 2023-04-26
IL296068A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
CO2022014093A2 (es) Compuestos para su uso en afecciones inflamatorias
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
DOP2018000010A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
GT201300128A (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
PA8740901A1 (es) Compuestos organicos
BR112012005970A2 (pt) moduladores tricíclicos de proteína quinase
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
CL2008002744A1 (es) Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
UY32675A (es) Nuevos agonistas del receptor de glucocorticoides
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CO6620038A2 (es) Compuestos de adenosina y su uso
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
SV2011003784A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112022007648A2 (pt) Tratamento de condições epilépticas com moduladores do receptor gabaa
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
CL2008003930A1 (es) Compuestos derivados de 2-benzoil-imidazo[1,2-a]piridina, moduladores de los receptores nucleares nurr1; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas,inflamatorias, osteoporosis, cancer, entre otras.
BR112023005398A2 (pt) Novo uso de um extrato de epilobium fleischeri